Navigation Links
Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
Date:1/16/2009

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters.

During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006.

"Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, PhD, senior vice president and general manager for the Healthcare business of Thomson Reuters.

The study is based on medical and drug claims data from the Thomson Reuters MarketScan(R) Research Databases. Results were weighted to reflect the U.S. population with employer-sponsored health insurance.

Researchers found a 50-percent increase in the use of prescription sleep aids among all adults under age 45 from 1998 to 2006. The most dramatic increase was seen in the youngest segment of the study population, those between the ages of 18 and 24, whose prevalence of use increased from 599 users per 100,000 in 1998 to 1,524 users per 100,000 in 2006. For those 25 to 34 years of age, use almost doubled from 1,372 users to 2,528 users per 100,000.

Non-benzodiazepine hypnotics -- such as Ambien CR and Lunesta -- accounted for almost two-thirds of all the prescription sleep aids used by this population.

A number of psychiatric, cognitive and conditioning factors are known to perpetuate insomnia, and the study found that 25 percent of first-time sleep aid users had a mental heath diagnosis in the month prior to sleep aid use. However, fewer than 10 percent of these new users visited a mental health professional prior to initiating sleep aid use. Most prescriptions were provided by family-practice physicians, acute care hospitals and doctors specializing in internal medicine and obstetrics/gynecology.

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Healthcare Cancer Profiler Used in Study
2. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
6. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
7. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
8. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
9. VA-NIH Study Offers Hope for Parkinsons Patients
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
(Date:2/23/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... release fourth quarter and yearly financial results after ... management will host an investment-community conference call at ... on March 2 nd 2017 to discuss ...
(Date:2/23/2017)... , February 23, 2017 ... from increasing caseload for varicose veins in their body. ... globe are prompting the adoption of endovenous laser therapy ... global endovenous laser therapy market, published by ... of lifestyle choices and consequences of obesity have collectively ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... York (PRWEB) , ... February 23, 2017 , ... Curemark, ... the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now ... clinical sites already enrolling children across the United States. , “There are currently ...
Breaking Medicine News(10 mins):